Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review.
Oronzo BrunettiAngela CalabreseLoredana PalermoAntonio Giovanni SolimandoAntonella ArgentieroPublished in: Clinical case reports (2019)
Two phase 3 trials reported a prolonged survival in the third-line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.